Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)

被引：0
|
作者：
Lipton, JH
Gospodarowicz, M
Reingold, S
机构：
[1] PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED,TORONTO,ON M4X 1K9,CANADA
[2] PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT RADIAT ONCOL,TORONTO,ON M4X 1K9,CANADA
[3] UNIV TORONTO,TORONTO,ON,CANADA
[4] PEEL MEM HOSP,DEPT MED,BRAMPTON,ON,CANADA
来源：
HEMATOLOGICAL ONCOLOGY | 1996年 / 14卷 / 01期
关键词：
acute myeloid leukemia; Hodgkin's disease; ABVD; radiation therapy; secondary leukemia;
D O I：
10.1002/(SICI)1099-1069(199603)14:1<29::AID-HON561>3.0.CO;2-J
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A 26-year-old man developed myelodysplasia rapidly progressing to acute myelomonocytic leukemia 3 years after receiving three cycles of ABVD chemotherapy and upper mantle and upper abdomen radiotherapy for stage IA Hodgkin's disease. This represents the fourth such case reported. The risk of secondary AML after ABVD or radiation therapy is discussed.
引用
收藏
页码：29 / 31
页数：3
相关论文
共 50 条
  • [41] Prediction of outcome according to international prognostic score (IPS) inpatients with advanced stage human immunodeficiency virus infection (HIV)-related hodgkin's lymphoma (HL) treated with doxorubicin, bleomycin,vinblastine and dacarbazine (ABVD) and highly active antiretroviral therapy (HAART)
    Xicoy, B.
    Ribera, J. M.
    Miralles, P.
    Berenguer, J.
    Rubio, R.
    Mahillo, B.
    Valencia, M. E.
    Abella, E.
    Lopez-Guillermo, A.
    Sureda, A.
    Morgades, M.
    Navarro, J. T.
    Esteban, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 67 - 67
  • [42] Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma
    Torka, Pallawi
    Feldman, Tatyana
    Savage, Kerry J.
    Ganesan, Nivetha
    Drill, Esther
    Hancock, Helen
    Davey, Theresa
    Perez, Leslie
    Capadona, Charisse
    Subzwari, Sarima
    Galasso, Natasha
    Yang, Jinshu
    Post, Michelle
    Boardman, Alexander
    Caron, Philip
    David, Kevin
    Epstein-Peterson, Zachary
    Falchi, Lorenzo
    Ghione, Paola
    Hamlin, Paul
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Johnson, William
    Kumar, Anita
    Lue, Jennifer
    Noy, Ariela
    Owens, Colette
    Palomba, M. Lia
    Salles, Gilles A.
    Steiner, Raphael
    Stuver, Robert
    Vardhana, Santosha
    Yahalom, Joachim
    Dogan, Ahmet
    Zelenetz, Andrew D.
    Schoder, Heiko
    Moskowitz, Alison J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
  • [43] LOMUSTINE, ETOPOSIDE, VINDESINE, AND DEXAMETHASONE (CEVD) IN HODGKINS LYMPHOMA REFRACTORY TO CYCLOPHOSPHAMIDE, VINCRISTINE, PROCARBAZINE, AND PREDNISONE (COPP) AND DOXORUBICIN, BLEOMYCIN, VINBLASTINE, AND DACARBAZINE (ABVD) - A MULTICENTER TRIAL OF THE GERMAN-HODGKIN-STUDY-GROUP
    PFREUNDSCHUH, MG
    SCHOPPE, WD
    FUCHS, R
    PFLUGER, KH
    LOEFFLER, M
    DIEHL, V
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1203 - 1207
  • [44] Secondary acute myeloid leukemia early after therapy for Hodgkin's disease - a case report
    Mihailov, G.
    Ganeva, P.
    Vassileva, N.
    Guenova, M.
    Balacenko, G.
    Toshkov, S.
    Hodjadjik, D.
    JOURNAL OF BUON, 2007, 12 (03): : 403 - 406
  • [45] Factors affecting relative dose intensity in patients with Hodgkin lymphoma (HL) receiving doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) without granulocyte-colony stimulating factor (G-CSF) support
    Kirui, L. C.
    Cwynarski, K.
    McNamara, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 53 - 53
  • [46] Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and Dacarbazine-Like chemotherapy regimen followed by extended-field, full-dose radiotherapy
    Djeridane, M
    Oudard, S
    Escoffre-Barbe, M
    Lacotte-Thierry, L
    Desablens, B
    Briére, J
    Dib, M
    Cassasus, P
    Ghandour, C
    Lamy, T
    Lejeune, F
    Simon, M
    Traullé, C
    Vigier, M
    Maisonneuve, H
    Briére, J
    Colonna, P
    Andrieu, JM
    CANCER, 2002, 95 (10) : 2169 - 2179
  • [47] Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
    Lagerlof, Ingemar
    Fohlin, Helena
    Enblad, Gunilla
    Glimelius, Bengt
    Goldkuhl, Christina
    Palma, Marzia
    Akesson, Lisa
    Glimelius, Ingrid
    Molin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1487 - 1496
  • [48] Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data? Reply
    Canellos, George
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : E487 - E487
  • [49] Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine
    Xicoy, Blanca
    Miralles, Pilar
    Morgades, Mireia
    Rubio, Rafael
    Valencia, Maria-Eulalia
    Ribera, Josep-Maria
    HAEMATOLOGICA, 2013, 98 (08) : E85 - E86
  • [50] HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
    Montoto, Silvia
    Shaw, Kate
    Okosun, Jessica
    Gandhi, Shreyans
    Fields, Paul
    Wilson, Andrew
    Shanyinde, Milensu
    Cwynarski, Kate
    Marcus, Robert
    de Vos, Johannes
    Young, Anna Marie
    Tenant-Flowers, Melinda
    Orkin, Chloe
    Johnson, Margaret
    Chilton, Daniella
    Gribben, John G.
    Bower, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4111 - 4116
12345